Broijersen, A. Et Al. 2019. Safety and tolerability of SOBI003 in pediatric MPS IIIA patients key study design features of the ongoing first-in-human study. 15th Annual Research Meeting of the WORLDSymposium(TM) , (Florida, United States Of America).

Broijersen, A., Dalen, P., Ezgu, F. S., Huledal, G., Lindqvist, D., Wiken, M., ... Harmatz, P.(2019). Safety and tolerability of SOBI003 in pediatric MPS IIIA patients key study design features of the ongoing first-in-human study . 15th Annual Research Meeting of the WORLDSymposium(TM), Florida, United States Of America

Broijersen, Anders Et Al. "Safety and tolerability of SOBI003 in pediatric MPS IIIA patients key study design features of the ongoing first-in-human study," 15th Annual Research Meeting of the WORLDSymposium(TM), Florida, United States Of America, 2019

Broijersen, Anders Et Al. "Safety and tolerability of SOBI003 in pediatric MPS IIIA patients key study design features of the ongoing first-in-human study." 15th Annual Research Meeting of the WORLDSymposium(TM) , Florida, United States Of America, 2019

Broijersen, A. Et Al. (2019) . "Safety and tolerability of SOBI003 in pediatric MPS IIIA patients key study design features of the ongoing first-in-human study." 15th Annual Research Meeting of the WORLDSymposium(TM) , Florida, United States Of America.

@conferencepaper{conferencepaper, author={Anders Broijersen Et Al. }, title={Safety and tolerability of SOBI003 in pediatric MPS IIIA patients key study design features of the ongoing first-in-human study}, congress name={15th Annual Research Meeting of the WORLDSymposium(TM)}, city={Florida}, country={United States Of America}, year={2019}}